KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals (NASDAQ: KALV) has granted inducement options to nine newly-hired employees. The options allow for the purchase of a total of 55,000 shares of KalVista common stock at an exercise price of $12.37 per share, matching the closing price on September 3, 2024. These options vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. The grants, made under KalVista's Inducement Equity Incentive Plan, are subject to continued employment and have a 10-year term. This action aligns with Nasdaq Listing Rule 5635(c)(4), which allows for inducement grants to new employees.
KalVista Pharmaceuticals (NASDAQ: KALV) ha concesso opzioni di indennizzo a nove nuovi dipendenti. Le opzioni consentono l'acquisto di un totale di 55.000 azioni ordinarie di KalVista a un prezzo di esercizio di $12,37 per azione, corrispondente al prezzo di chiusura del 3 settembre 2024. Queste opzioni maturano nel corso di quattro anni, con il 25% che matura dopo un anno e il restante che matura mensilmente nei successivi tre anni. Le concessioni, effettuate nell'ambito del Piano Incentivo Azionario per Indennizzi di KalVista, sono soggette a continua occupazione e hanno una durata di 10 anni. Questa azione è in linea con la Regola di Quotazione Nasdaq 5635(c)(4), che consente concessioni di indennizzo ai nuovi dipendenti.
KalVista Pharmaceuticals (NASDAQ: KALV) ha otorgado opciones de inducción a nueve nuevos empleados. Las opciones permiten la compra de un total de 55,000 acciones ordinarias de KalVista a un precio de ejercicio de $12.37 por acción, coincidiendo con el precio de cierre del 3 de septiembre de 2024. Estas opciones se consolidan durante cuatro años, con el 25% consolidándose después de un año y el resto consolidándose mensualmente durante los tres años siguientes. Las concesiones, realizadas bajo el Plan de Incentivos de Capital por Inducción de KalVista, están sujetas a empleo continuo y tienen un término de 10 años. Esta acción se alinea con la Regla de Cotización 5635(c)(4) de Nasdaq, que permite concesiones de inducción a nuevos empleados.
KalVista Pharmaceuticals (NASDAQ: KALV)는 새로 고용된 아홉 명의 직원에게 유인 옵션을 부여했습니다. 이 옵션은 KalVista의 보통주 55,000주를 $12.37 per share의 행사 가격으로 매입할 수 있게 합니다. 이는 2024년 9월 3일의 종가와 일치합니다. 이러한 옵션은 4년에 걸쳐 만료되며, 1년 후 25%가 확정되고 나머지는 다음 3년 동안 매월 확정됩니다. KalVista의 유인 자본 인센티브 계획에 따라 이루어진 이 보상은 지속적인 고용을 조건으로 하며 10년의 유효 기간을 가집니다. 이 조치는 신규 직원에 대한 유인 보상 허용을 규정한 나스닥 상장 규칙 5635(c)(4)과 일치합니다.
KalVista Pharmaceuticals (NASDAQ: KALV) a accordé des options d'induction à neuf nouveaux employés. Les options permettent l'achat d'un total de 55 000 actions ordinaires de KalVista à un prix d'exercice de 12,37 $ par action, correspondant au prix de clôture du 3 septembre 2024. Ces options s'acquièrent sur une période de quatre ans, avec 25 % qui s'acquièrent après un an et le reste s'acquérant mensuellement au cours des trois années suivantes. Les attributions, effectuées dans le cadre du Plan d'Incitations en Actions de KalVista, sont soumises à un emploi continu et ont une durée de 10 ans. Cette action est conforme à la règle de cotation Nasdaq 5635(c)(4), qui permet des attributions d'incitation aux nouveaux employés.
KalVista Pharmaceuticals (NASDAQ: KALV) hat neun neu eingestellten Mitarbeitern Anreizoptionen gewährt. Die Optionen ermöglichen den Kauf von insgesamt 55.000 Stammaktien von KalVista zu einem Ausübungspreis von $12,37 pro Aktie, was dem Schlusskurs am 3. September 2024 entspricht. Diese Optionen werden über einen Zeitraum von vier Jahren fällig, wobei 25% nach einem Jahr und der Rest in den folgenden drei Jahren monatlich fällig wird. Die Zuwendungen, die im Rahmen des Anreiz-Eigenkapitalplans von KalVista erfolgen, sind an eine fortgesetzte Beschäftigung gebunden und haben eine Laufzeit von 10 Jahren. Diese Maßnahme ist mit der Nasdaq-Listing-Regel 5635(c)(4) vereinbar, die Anreizgewährungen an neue Mitarbeiter erlaubt.
- Attraction of new talent with stock options as incentives
- Alignment of employee interests with company performance through equity grants
- Potential dilution of existing shareholders' stake due to new stock options
The options have an exercise price of
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company focused on the development and delivery of oral medicines for diseases with significant unmet need. KalVista announced positive phase 3 data from the KONFIDENT trial for its oral, on-demand therapy, sebetralstat for HAE in February 2024. The Company’s NDA for sebetralstat has been accepted by the FDA with a PDUFA goal date of June 17, 2025. In addition, KalVista received validation of its MAA from the EMA in August 2024. KalVista expects to file for approval in the
For more information about KalVista, please visit www.kalvista.com or follow on social media at @KalVista and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904377554/en/
KalVista Pharmaceuticals, Inc.
Media:
Jenn Snyder
Vice President, Corporate Affairs
(857) 356-0479
jennifer.snyder@kalvista.com
Investors:
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
Source: KalVista Pharmaceuticals, Inc.
FAQ
How many shares of KALV stock were granted as inducement options on September 3, 2024?
What is the exercise price of the KALV stock options granted on September 3, 2024?
What is the vesting schedule for the KALV inducement options granted?
How long is the term of the KALV stock options granted as inducements?
